DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Windlas Biotech Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·7 Oct 2026, 8:21 am

Windlas Biotech

Windlas Biotech Limited has informed stock exchanges that it has received a Certificate of Compliance under the SEBI (Depositories and Participants) Regulations, 2018. This regulatory requirement is mandatory for companies to ensure they have a proper and compliant Depository Participant (DP) relationship in place.

For investors, this news is largely procedural and confirms that the company is adhering to standard corporate governance norms regarding its shareholding structure. It does not indicate any operational change or financial distress. The compliance certificate is a routine filing that validates the company's adherence to market regulations.

Investors should monitor the company's future quarterly results to see if this regulatory clarity translates into any operational improvements. As this is a standard compliance update, it is not expected to cause significant volatility in the stock price.